The Atriva Company
Atriva Therapeutics – When prevention fails: host-targeting therapy for severe viral disease
Atriva Therapeutics is a biopharmaceutical company pioneering the development of first-in-class host-cell-targeting antiviral and immunomodulatory therapies. The company was set up by a team of leading scientists in viral disease research and industry experts with a proven track record. Atriva aims to develop novel, highly efficacious and safe therapies for the treatment of severe diseases caused by RNA-viruses with a high unmet medical need and huge cost burden to healthcare systems around the world such as influenza virus, respiratory syncytial virus infections, dengue fever and hanta virus infections.
Atriva’s lead product zapnometinib (previously known as ATR-002) is a novel, first-in-class host-cell-targeting, orally available small molecule drug inhibiting viral replication and rebalancing the body’s immune response. Zapnometinib has successfully completed a Phase I clinical trial to demonstrate safety and tolerability in healthy volunteers (NCT04385420). A Phase II study (NCT04776044) to evaluate the efficacy and safety of zapnometinib in hospitalized patients with severe COVID-19 obtained approval from Germany`s regulatory authority (BfArM) and generated very promising results. They underpin zapnometinib`s mechanism of action, efficacy against RNA-based virus infections and the safe use in humans. Going forward, Atriva will focus resources on the development of zapnometinib for the treatment of patients hospitalized with severe influenza infections.
Due to its mechanism of action with dual benefit – antiviral activity combined with immunomodulation – zapnometinib is uniquely positioned as a highly promising therapeutic candidate for the treatment of severe RNA-virus infections. By treating severe viral infections, Atriva strives to significantly reduce the number of critically sick patients, which would otherwise be referred to ICUs and require more invasive and vastly more expensive treatment options. Consequently, zapnometinib bears the potential to fundamentally improve the outcome of severe virus infections resulting in massive savings for entire societies and their national health care systems.